Pfizer Inc (PFE) Makes Big Move Relative to Two Week Trend, Moves Up For the 2nd Day In A Row; Crosses 20 and 200 Day Moving Averages

(Nyse: pfe) today announced that the phase 3 spirit long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.